Catherine L. Salussolia | Medical Services
Specialties
Programs & Services
- Brain Development and Genetics Clinic
- Epilepsy Center
- Epilepsy Genetics Program
- Neurology
- Neuroscience Center
- Tuberous Sclerosis Program
Languages
- English
Catherine L. Salussolia | Education
Undergraduate School
Swarthmore College
2004, Swarthmore, PA
Graduate School
Stony Brook University
2012, Stony Brook, NY
Medical School
Stony Brook University
2014, Stony Brook, NY
Internship
Pediatrics
Stony Brook University
2015, Stony Brook, NY
Residency
Boston Children's Hospital
2019, Boston, MA
Fellowship
Clinical Neurophysiology and Epilepsy
Boston Children's Hospital
Catherine L. Salussolia | Certifications
- American Board of Psychiatry and Neurology (Child and Adolescent Neurology)
Catherine L. Salussolia | Professional History
Dr. Salussolia is a neurologist and epileptologist at Boston Children’s Hospital with board certification in neurology and special qualification in child neurology. She has fellowship training in epilepsy and clinical neurophysiology, as well as in neurogenetics, with a focus on epilepsy genetics and tuberous sclerosis. She is an attending physician in the Epilepsy Genetics Program and the Tuberous Sclerosis Clinic, through which she sees patients for consultations and management of epilepsy.
Dr. Salussolia obtained her Bachelor of Arts in Psychology with a minor in Biology from Swarthmore College. She completed a Masters in Science at Albany Medical College in the Neuropharmacology and Neuroscience, and then received her MD/PhD degrees through the MSTP program at Stony Brook University. Her doctoral work utilized molecular techniques to identify and characterize the biogenesis of ionotropic glutamate receptors (NMDA and AMPA receptors) and its effects on disease states. She completed her pediatrics training at Stony Brook University followed by child neurology residency and fellowship training in clinical neurophysiology and neurogenetics at Boston Children’s Hospital. Her current research focuses on the molecular mechanisms of inhibitory signaling, specifically parvalbumin interneurons, in tuberous sclerosis-associated epilepsy.